Exciting ESMO 2025 Highlights: Advanced Therapies from Akeso

Exciting ESMO 2025 Highlights from Akeso

Akeso Inc. (9926.HK) is thrilled to share significant advancements in cancer treatment as they prepare for the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. An important part of this event will be the Late-Breaking Abstract (LBA) featuring results from the Phase III clinical study of ivonescimab—a first-in-class bispecific antibody that targets PD-1 and VEGF. This study will showcase the treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) in a comparison against tislelizumab, another established therapy.

Key Presentation on Ivonescimab

The HARMONi-6 trial, led by the esteemed Professor Lu Shun from Shanghai Chest Hospital, will highlight compelling findings about ivonescimab in combination with chemotherapy. This study’s inclusion in the prestigious Presidential Symposium at ESMO reflects its significance in the scientific community. Presenting on a prestigious stage like this underscores the study's importance in paving the way for future treatment options in oncology.

What to Expect from the HARMONi-6 Study

During the presentation, attendees can anticipate in-depth insights into the efficacy and safety of ivonescimab. Data from this study will detail how the combination therapy improves patient outcomes, especially in maximizing progression-free survival (PFS). Importantly, these outcomes demonstrate ivonescimab’s transformative potential over first-generation immuno-oncology treatments, marking it as a pivotal step forward in cancer care.

Cadonilimab's Role in Advanced Gastric Cancer

In addition to ivonescimab, Akeso will also present results from the Phase III COMPASSION-15 clinical trial, which evaluates cadonilimab—another groundbreaking bispecific antibody targeting PD-1 and CTLA-4. Professor Shen Lin from Peking University Cancer Hospital will share the compelling data from this study on the treatment of unresectable gastric cancer. This presentation will be part of a Mini Oral Session at ESMO.

Impact of Cadonilimab in Clinical Practice

The COMPASSION-15 study's findings will reinforce cadonilimab's status as a transformative option in treating advanced gastric adenocarcinoma. With successful approval by regulatory agencies earlier this year, the drug's emerging data reflects its promising capabilities and the changing landscape of gastric cancer treatment. The inclusion of cadonilimab in the 2025 CSCO Gastric Cancer Guidelines further cements its position as a leading therapy and paves the way for better outcomes for patients worldwide.

Looking Forward: Akeso's Vision

Akeso's focus extends beyond these specific studies. The company is clearly dedicated to expanding their innovative pipeline. As they explore therapies for various disease states, their commitment to bridging the gap between traditional and novel treatment strategies remains a priority. This includes advancing treatment methodologies that not only improve health outcomes but also provide accessible medicine globally.

Frequently Asked Questions

What are the highlights of Akeso's presentations at ESMO 2025?

Akeso will showcase pivotal findings from the HARMONi-6 study on ivonescimab and the COMPASSION-15 trial on cadonilimab, indicating promising advancements in cancer treatment.

What is ivonescimab, and why is it significant?

Ivonescimab is a novel bispecific antibody targeting PD-1 and VEGF, promising to improve treatment strategies for advanced sq-NSCLC compared to existing therapies.

Who will present the studies at the conference?

Professor Lu Shun will present the HARMONi-6 results, while Professor Shen Lin will discuss findings from the COMPASSION-15 trial.

How does cadonilimab compare to other treatments?

Cadonilimab has shown transformative potential in treating advanced gastric cancer, outperforming many existing therapies and is recognized in national guidelines.

What is Akeso's overarching goal in cancer treatment?

Akeso aims to develop first-in-class therapies and enhance treatment efficacy across various cancers while ensuring global access to innovative medicines.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.